Individualizing calcineurin inhibitor therapy in renal transplantation - Current limitations and perspectives

Current Pharmaceutical Design

Volumn 16, Issue 2, 2010, Pages 176-186

  Press, R R ^a   De Fijter, J W ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Calcineurin; Immunophilin; NFAT; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Systems pharmacology

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOPHILIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOPROTEIN P; IMMUNOPHILIN; PREGNANE X RECEPTOR; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ALLELE; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG TARGETING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT REJECTION; HUMAN; INDIVIDUALIZATION; KIDNEY TRANSPLANTATION; MEDICAL RESEARCH; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

CALCINEURIN; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TACROLIMUS;

EID: 77949437369     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790112782     Document Type: Review

References (161)

1. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66(12): 1736-40.
2. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008; 86(6): 761-7.
3. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357(25): 2562-75.
4. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31(5): 309-16.
5. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68(1): 55-62.
6. Clase CM, Mahalati K, Kiberd BA, Lawen JG, West KA, Fraser AD, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2(8): 789-95.
7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43(10): 623-53.
8. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4(6): 914-9.
9. Yano I. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Drug Metab Pharmacokinet 2008; 23(3): 150-7.
10. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72(6): 660-9.
11. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64(6): 750-7.
12. Moller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1999; 27(6): 633-6.
13. Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005; 33(9): 1268-75.
14. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heijden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76(6): 545-56.
15. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, Bernard N, Thiry P, Le Meur Y, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006; 45(9): 905-22.
16. Fanta S, Niemi M, Jonsson S, Karlsson MO, Holmberg C, Neuvonen PJ, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008; 18(2): 77-90.
17. Karamperis N, Povlsen JV, Hojskov C, Poulsen JH, Pedersen AR, Jorgensen KA. Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. Transplant Proc 2003; 35(4): 1314-8.
18. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000; 68(5): 478-86.
19. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23(12): 1315-24.
20. van Duijnhoven E, Christiaans M, Schafer A, Undre N, van Hooff J. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998; 30(4): 1266-7.
21. Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol 1994; 34(1): 60-7.
22. van Duijnhoven E, Christiaans M, Undre N, Stevenson P, van Hooff J. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 1998; 30(4): 1268-70.
23. Sato K, Amada N, Sato T, Miura S, Ohashi Y, Sekiguchi S, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 2004; 18(5): 585-90.
24. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002; 62(10): 1481-1502.
25. McMillan MA. Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 1989; 42(1): 135-56.
26. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41(11): 813-51.
27. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62(3): 248-60.
28. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004; 4(9): 1514-22.
29. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33(6): 680-2.
30. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39(1): 91-6.
31. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62(1): 41-9.
32. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58(1): 15-9.
33. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52(5): 453-7.
34. Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 2006; 79(3): 255-62.
35. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57(5): 485-91.
36. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit 2004; 26(5): 506-15.
37. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004; 57(3): 298-309.
38. Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 2001; 46(1): 27-35.
39. Huang ML, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE. Drug-binding proteins in liver transplant patients. J Clin Pharmacol 1988; 28(6): 505-6.
40. Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002; 41(9): 615-37.
41. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998; 30(4): 1261-3.
42. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004; 43(11): 741-62.
43. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66(4): 807-15.
44. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75(1): 13-33.
45. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67(6): 2440-7.
46. Cremers SC, Scholten EM, Schoemaker RC, Lentjes EG, Vermeij P, Paul LC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003; 18(6): 1201-8.
47. Buchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, et al. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases. Nephrol Dial Transplant 2006; 21(1): 197-202.
48. Legg B, Gupta SK, Rowland M, Johnson RW, Solomon LR. Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. Eur J Clin Pharmacol 1988; 34(5): 451-60.
49. Vine W, Flye MW, Jatlow P. Relationships of cyclosporine concentrations in serum, whole blood, and bile after renal and hepatic transplantation. Clin Chem 1986; 32(10): 1828-31.
50. Rosano TG. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients. Clin Chem 1985; 31(3): 410-2.
51. Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. J Pharm Pharmacol 1987; 39(8): 599-603.
52. Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002; 17(8): 1487-90.
53. Marin JG, Levine M, Ensom MH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006; 28(5): 637-42.
54. Kyllonen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. Transplantation 2006; 81(7): 1010-5.
55. Einecke G, Schutz M, Mai I, Fritsche L, Giessing M, Glander P, et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005; 20(7): 1463-70.
56. Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu YM, et al. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation 2005; 80(7): 910-6.
57. Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardo LM, Chadban S, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76(6): 903-8.
58. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6(4): 369-83.
59. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11(7): 555-72.
60. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007; 47(5): 566-78.
61. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62(3): 638-46.
62. Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol 2007; 21(4): 176-81.
63. He P, Court MH, Greenblatt DJ, von Moltke LL. Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 2006; 46(11): 1356-69.
64. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004; 279(37): 38379-85.
65. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34(5): 836-47.
66. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51(8): 1374-81.
67. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76(8): 1233-5.
68. Hesselink DA, van Schaik RH, van der Heijden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74(3): 245-54.
69. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14(7): 471-8.
70. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19(5): 638-43.
71. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78(8): 1182-7.
72. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De MM, Eddour DC, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006; 6(11): 2706-13.
73. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 2007; 64(2): 185-91.
74. Hesselink DA, van Schaik RH, van AM, de Fijter JW, Hartmann A, Zeier M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18(4): 339-48.
75. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103(6): 546-52.
76. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7(9): 2114-23.
77. Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16(9): 659-65.
78. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6(1): 37-47.
79. Thorn M, Lundgren S, Herlenius G, Ericzon BG, Loof L, Rane A. Gene expression of cytochromes P450 in liver transplants over time. Eur J Clin Pharmacol 2004; 60(6): 413-20.
80. Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004; 26(5): 524-8.
81. Anglicheau D, Thervet E, Etienne I, Hurault De LB, Le Meur Y, Touchard G, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75(5): 422-33.
82. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 2004; 78(3): 311-5.
83. Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005; 6(2): 163-8.
84. Haufroid V, Mourad M, Van KV, Wawrzyniak J, De MM, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14(3): 147-54.
85. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004; 58(5): 548-53.
86. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14(7): 1889-96.
87. Hesselink DA, van Schaik RH, Nauta J, van GT. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics 2008; 9(6): 783-9.
88. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005; 94(6): 1169-86.
89. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8(2): 307-16.
90. Hesselink DA, Ngyuen H, Wabbijn M, Gregoor PJ, Steyerberg EW, van Riemsdijk IC, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003; 56(3): 327-30.
91. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18(11): 2409-14.
92. van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16(10): 721-5.
93. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008; 73(11): 1052-9.
94. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 2008; 18(4): 307-15.
95. Elliott JI, Raguz S, Higgins CF. Multidrug transporter activity in lymphocytes. Br J Pharmacol 2004; 143(7): 899-907.
96. Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation 2008; 85(2): 179-84.
97. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 2005; 25(6): 779-89.
98. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204(3): 216-37.
99. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16(5): 1501-11.
100. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30(10): 1108-14.
101. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82(6): 711-25.
102. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation - how much of the promise has been realized? Nat Med 2005; 11(6): 605-13.
103. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351(26): 2715-29.
104. Sugiura R, Sio SO, Shuntoh H, Kuno T. Molecular genetic analysis of the calcineurin signaling pathways. Cell Mol Life Sci 2001; 58(2): 278-88.
105. Hemenway CS, Heitman J. Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys 1999; 30(1): 115-51.
106. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17(18): 2205-32.
107. Hogan PG, Li H. Calcineurin. Curr Biol 2005; 15(12): R442-3.
108. Kahan BD. Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol 2003; 3(10): 831-8.
109. Soldin SJ, Murthy JN, Donnelly JG, Chen Y, Goodyear N. Immunophilin receptors for immunosuppressive drugs. Ther Drug Monit 1993; 15(6): 468-71.
110. Jin L, Harrison SC. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci USA 2002; 99(21): 13522-6.
111. Fukudo M, Yano I, Masuda S, Okuda M, Inui K. Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity. J Pharmacol Exp Ther 2005; 312(2): 816-25.
112. Sellar KJ, van Rossum HH, Romijn FP, Smit NP, de Fijter JW, van Pelt J. Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood. Anal Biochem 2006; 358(1): 104-10.
113. Blanchet B, Hulin A, Duvoux C, Astier A. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. Anal Biochem 2003; 312(1): 1-6.
114. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68(9): 1356-61.
115. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003; 57(2): 93-8.
116. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, Jorgensen KA. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant 2002; 2(2): 173-8.
117. Millan O, Brunet M, Campistol JM, Faura A, Rojo I, Vidal E, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003; 49(11): 1891-9.
118. Koefoed-Nielsen PB, Karamperis N, Hojskov C, Poulsen JH, Jorgensen KA. The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients. Transpl Int 2006; 19(10): 821-7.
119. Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant 2008; 8(7): 1374-83.
120. Liu L, Zhang J, Yuan J, Dang Y, Yang C, Chen X, et al. Characterization of a human regulatory subunit of protein phosphatase 3 gene (PPP3RL) expressed specifically in testis. Mol Biol Rep 2005; 32(1): 41-5.
121. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 1998; 273(22): 13367-70.
122. Guerini D. Calcineurin: not just a simple protein phosphatase. Biochem Biophys Res Commun 1997; 235(2): 271-5.
123. Wang HL, Du YW, Xiang BQ, Lin WL, Wei Q. The regulatory domains of CNA have different effects on the inhibition of CN activity by FK506 and CsA. IUBMB Life 2007; 59(6): 388-93.
124. Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant 2001; 1(4): 325-33.
125. Muramatsu T, Kincaid RL. Molecular cloning of a full-length cDNA encoding the catalytic subunit of human calmodulin-dependent protein phosphatase (calcineurin A alpha). Biochim Biophys Acta 1993; 1178(1): 117-20.
126. Jiang H, Xiong F, Kong S, Ogawa T, Kobayashi M, Liu JO. Distinct tissue and cellular distribution of two major isoforms of calcineurin. Mol Immunol 1997; 34(8-9): 663-9.
127. Wang MG, Yi H, Guerini D, Klee CB, McBride OW. Calcineurin A alpha (PPP3CA), calcineurin A beta (PPP3CB) and calcineurin B (PPP3R1) are located on human chromosomes 4, 10q21- >q22 and 2p16 - >p15 respectively. Cytogenet Cell Genet 1996; 72(2-3): 236-41.
128. Stemmer PM, Klee CB. Dual calcium ion regulation of calcineurin by calmodulin and calcineurin B. Biochemistry 1994; 33(22): 6859-66.
129. Wang H, Yao S, Lin W, Du Y, Xiang B, He S, et al. Different roles of Loop 7 in inhibition of calcineurin. Biochem Biophys Res Commun 2007; 362(2): 263-8.
130. Ke H, Zhao Y, Luo F, Weissman I, Friedman J. Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A. Proc Natl Acad Sci USA 1993; 90(24): 11850-4.
131. Zydowsky LD, Etzkorn FA, Chang HY, Ferguson SB, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci 1992; 1(9): 1092-9.
132. Colgan J, Asmal M, Yu B, Luban J. Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol 2005; 174(10): 6030-8.
133. Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J 1994; 8(6): 391-400.
134. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 2000; 70(2): 327-35.
135. An P, Wang LH, Hutcheson-Dilks H, Nelson G, Donfield S, Goedert JJ, et al. Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog 2007; 3(6): e88.
136. Mikol V, Kallen J, Pflugl G, Walkinshaw MD. X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J Mol Biol 1993; 234(4): 1119-30.
137. Moscoso-Solorzano GT, Ortega F, Rodriguez I, Garcia-Castro M, Gomez E, az-Corte C, et al. A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients. Clin Transplant 2008; 22(6): 722-9.
138. Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 2006; 45(51): 15776-84.
139. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-47.
140. Luo C, Burgeon E, Carew JA, McCaffrey PG, Badalian TM, Lane WS, et al. Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. Mol Cell Biol 1996; 16(7): 3955-66.
141. Crabtree GR. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999; 96(5): 611-4.
142. Martinez-Martinez S, Rodriguez A, Lopez-Maderuelo MD, Ortega-Perez I, Vazquez J, Redondo JM. Blockade of NFAT activation by the second calcineurin binding site. J Biol Chem 2006; 281(10): 6227-35.
143. Kang S, Li H, Rao A, Hogan PG. Inhibition of the calcineurin-NFAT interaction by small organic molecules reflects binding at an allosteric site. J Biol Chem 2005; 280(45): 37698-706.
144. Mourad M, Wallemacq P, De Meyer M, Malaise J, De Pauw L, Eddour DC, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008; 85(7 Suppl): S19-24.
145. Caruso R, Perico N, Cattaneo D, Piccinini G, Bonazzola S, Remuzzi G, et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem 2001; 47(9): 1679-87.
146. Enz A, Shapiro G, Chappuis A, Dattler A. Nonradioactive assay for protein phosphatase 2B (calcineurin) activity using a partial sequence of the subunit of cAMP-dependent protein kinase as substrate. Anal Biochem 1994; 216(1): 147-53.
147. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89(9): 3686-90.
148. Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Validation of the calcineurin phosphatase assay. Clin Chem 2004; 50(12): 2331-7.
149. van Rossum HH, Romijn FP, Sellar KJ, Smit NP, van der Boog PJ, de Fijter JW, et al. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. Clin Chem 2008; 54(3): 517-24.
150. Blanchet B, Hulin A, Ghaleh B, Giraudier S, Jouault H, Astier A. Distribution of calcineurin activity in blood cell fractions and impact of tacrolimus inhibition. Fundam Clin Pharmacol 2006; 20(2): 137-44.
151. Takemoto SK, Pinsky BW, Schnitzler MA, Lentine KL, Willoughby LM, Burroughs TE, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7(12): 2704-11.
152. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38(6 Suppl 6): S25-35.
153. Ichimaru N, Kakuta Y, Abe T, Okumi M, Imamura R, Isaka Y, et al. Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants. Transplant Proc 2008; 40(5): 1362-5.
154. Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant Proc 2007; 39(5): 1287-300.
155. Irtan S, Saint-Marcoux F, Rousseau A, Zhang D, Leroy V, Marquet P, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007; 29(1): 96-102.
156. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006; 80(4): 331-45.
157. Fukudo M, Yano I, Masuda S, Fukatsu S, Katsura T, Ogura Y, et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005; 78(2): 168-81.
158. Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A, et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit 2008; 30(4): 412-8.
159. Dalla Libera L, Vescovo G, Volterrani M. Physiological basis for contractile dysfunction in heart failure. Curr Pharm Des 2008; 14(25): 2572-81.
160. Thuillier R, Tillement JP, Hauet T. Renal protective effect of metabolic therapy in patients with coronary artery disease and diabetes: from bench to bed side. Curr Pharm Des 2009; 15(8): 863-82.
161. Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des 2009; 15(17): 1974-97.